Drug Solubilization Technologies Becoming Mainstream as Emphasis on Drug Reformulation Grows

Greystone Associates Analyzes Strategic and Technology Factors Influencing Product Formulation Decisions for a Range of Drugs

[USPRwire, Tue Sep 22 2009] As new tools for automating the drug discovery process yield potential drug candidates at an accelerating rate, attention is focusing on the areas of drug formulation and preclinical development as critical steps in the path to commercializing new chemical entities and driving the financial success of drug companies. More than ever before, drug formulation technology is now seen as a key enabler of new prescription products. Much of the current focus in formulation science is concerned with processes that can improve the solubility of APIs. The importance of solubilization technologies is also underscored by the capability they bestow on formulators attempting to re-formulate approved drugs approaching the end of their patent life.

“Issues surrounding water insolubility of active compounds have important business and market implications for new drug development,” explains George Perros, Greystone’s Managing Director. “This impact goes beyond potential future drug therapeutics, effectively limiting reformulation strategies for existing products at a time when extending the market life of proprietary drugs through derivative formulations has become a key business strategy.”

More than three-dozen companies are now promoting a broad range of drug solubilization technologies. These companies are working with drug developers at pharmaceutical companies around the world to help define the prescription formulations that will enter preclinical development and the clinical trial pipeline in the coming months and years.

Findings of a recent survey by Greystone are contained in a new and comprehensive report: Drug Solubilization: Evolving Technologies – Emerging Opportunities. The survey concludes that a top tier of established solubilization technologies will dominate this sector, accounting for more than two-thirds of all commercial solubility-enhanced drug formulations by 2012, based on the ability of selected contract drug developers possessing the tools to engineer water-soluble formulations of inherently hydrophobic compounds to efficiently manage client programs and bring re-formulation projects in on time. The report includes analysis and evaluations of drug solubility technologies, assessments of market and technology factors, and profiles of drug formulation technology companies.

More information is available at www.greystoneassociates.org .

About Greystone

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.


Contact:

Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org

Source: Greystone Associates